NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma

Role of    T Cells in  -Galactosylceramide-Mediated Immunity

(2012) C. Paget et al.   JOURNAL OF IMMUNOLOGY

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

(2010) D. M. Benson et al.   BLOOD

Advances in the understanding of MYC-induced lymphomagenesis

(2010) Kay Klapproth et al.   BRITISH JOURNAL OF HAEMATOLOGY

Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans

(2010) Leonid S. Metelitsa   CLINICAL IMMUNOLOGY

IL-18, but not IL-15, contributes to the IL-12-dependent induction of NK-cell effector functions by Leishmania infantum in vivo

(2010) Simone Haeberlein et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Secretion of IFN-  but Not IL-17 by CD1d-Restricted NKT Cells Enhances Rejection of Skin Grafts Expressing Epithelial Cell-Derived Antigen

(2010) S. R. Mattarollo et al.   JOURNAL OF IMMUNOLOGY

Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi

(2010) Johannes Zuber et al.   NATURE BIOTECHNOLOGY

Raising the NKT cell family

(2010) Dale I Godfrey et al.   NATURE IMMUNOLOGY

The Contrasting Roles of NKT Cells in Tumor Immunity

(2009) Jay Berzofsky et al.   CURRENT MOLECULAR MEDICINE

Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma

(2008) G. J. Renukaradhya et al.   BLOOD

MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma

(2008) M. Jinushi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA